Publication | Open Access

Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial

VaccinationVaccine SafetyPhase 1/2Vaccine TargetImmunologyVaccine TestingDose-ranging TrialVaccine EfficacyMedicineCovid-19